Abstract
The nuclear hormone receptor peroxisome proliferator-activated receptor-gamma (PPAR-gamma) may play a role in prostate carcinogenesis. We examined the association between the PPAR-gamma Pro12Ala polymorphism and prostate cancer risk in a cohort of Finnish male smokers. In a nested case-control analysis that included 193 prostate cancer cases and 188 matched controls, we found no significant association between this polymorphism and prostate cancer risk (odds ratio, OR=1.27, 95% confidence interval, CI: 0.83-1.94), or significant trend or association with tumor stage (OR=1.28, 95% CI: 0.54-3.04 for metastatic disease) or grade (OR=1.57, 95% CI: 0.63-3.91 for poorly differentiated disease). The Pro12Ala polymorphism does not appear to play a significant role in prostate cancer risk in this cohort of men.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / epidemiology*
-
Adenocarcinoma / genetics
-
Adenocarcinoma / pathology
-
Adenocarcinoma / prevention & control
-
Aged
-
Amino Acid Substitution*
-
Anticarcinogenic Agents / therapeutic use
-
Case-Control Studies
-
Cell Differentiation
-
Cohort Studies
-
DNA Mutational Analysis
-
Finland / epidemiology
-
Genetic Predisposition to Disease
-
Genotype
-
Humans
-
Incidence
-
Male
-
Middle Aged
-
Odds Ratio
-
Polymorphism, Single Nucleotide*
-
Prostatic Neoplasms / epidemiology*
-
Prostatic Neoplasms / genetics
-
Prostatic Neoplasms / pathology
-
Prostatic Neoplasms / prevention & control
-
Receptors, Cytoplasmic and Nuclear / genetics*
-
Receptors, Cytoplasmic and Nuclear / physiology
-
Risk
-
Smoking / epidemiology
-
Transcription Factors / genetics*
-
Transcription Factors / physiology
-
alpha-Tocopherol / therapeutic use
-
beta Carotene / therapeutic use
Substances
-
Anticarcinogenic Agents
-
Receptors, Cytoplasmic and Nuclear
-
Transcription Factors
-
beta Carotene
-
alpha-Tocopherol